ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure
On October27, 2017, ContraVir Pharmaceuticals,Inc. mailed its 2017 letter to its stockholders as well as posted it on its website at www.contravir.com.
The information in this Current Report shall not be deemed “soliciting material” or “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits
(d)Exhibits
|
99.1 |
ContraVirPharmaceuticals,Inc.2017StockholdersLetter |
ContraVir Pharmaceuticals, Inc. ExhibitEX-99.1 2 a17-24567_1ex99d1.htm EX-99.1 Exhibit 99.1 ContraVir Pharmaceuticals Provides Corporate Update and Reports 2017 Financial and Operational Results Dear Shareholder,…To view the full exhibit click here
About ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV)
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company’s CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company’s CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company’s FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. It has developed FV-100 for the treatment of shingles.
